DongKoo Bio & Pharma Co., Ltd. (KOSDAQ: 006620)

Market Cap	133.64B
Revenue (ttm)	240.39B
Net Income (ttm)	13.00B
Shares Out	27.30M
EPS (ttm)	471.99
PE Ratio	10.37
Forward PE	n/a
Dividend	120.00 (2.45%)
Ex-Dividend Date	n/a

Volume	194,411
Open	4,740.00
Previous Close	4,815.00
Day's Range	4,640.00 - 4,910.00
52-Week Range	4,640.00 - 8,990.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About DongKoo Bio & Pharma

DongKoo Bio & Pharma Co., Ltd. manufactures and sells pharmaceuticals in South Korea. The company provides prescription drugs, such as antihistamines, dermatological oral medications, ophthalmic solutions, skeletal muscle relaxants, anti-inflammatory enzymes, antivirals, antibacterial agents, and for the treatment of allergies, liver diseases, mental illnesses, obesity, brain nervous, and endocrine systems; over-the-counter medicines, such as dermatological external preparations, antifungal agents, active probiotic intestinal supplements, antip...

• Industry: Pharmaceutical Preparations
• Founded: 1970
• Employees: 375
• Stock Exchange: KOSDAQ
• Ticker Symbol: 006620

Financial Performance

In 2023, DongKoo Bio & Pharma's revenue was 215.69 billion, an increase of 10.62% compared to the previous year's 194.99 billion. Earnings were 11.81 billion, an increase of 78.59%.